These results support our assertion that PGRMC1 regulates EGFR, and that AKT and mTOR are downstream targets, whereas PTEN inhibits PGRMC1 downstream signalling in breast cancers (Fig. 6i). This evidence concerns the gene PTEN and breast carcinoma.